HomeCompareTLKMF vs ABBV

TLKMF vs ABBV: Dividend Comparison 2026

TLKMF yields 8.19% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $55.4K in total portfolio value· pulled ahead in Year 2
10 years
TLKMF
TLKMF
● Live price
8.19%
Share price
$0.16
Annual div
$0.01
5Y div CAGR
9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$46.9K
Annual income
$4,206.70
Full TLKMF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TLKMF vs ABBV

📍 ABBV pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTLKMFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TLKMF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TLKMF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TLKMF
Annual income on $10K today (after 15% tax)
$695.94/yr
After 10yr DRIP, annual income (after tax)
$3,575.69/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $17,480.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TLKMF + ABBV for your $10,000?

TLKMF: 50%ABBV: 50%
100% ABBV50/50100% TLKMF
Portfolio after 10yr
$74.6K
Annual income
$14,489.23/yr
Blended yield
19.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TLKMF
Analyst Ratings
2
Hold
Consensus: Hold
Altman Z
3.0
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TLKMF buys
0
ABBV buys
0
No recent congressional trades found for TLKMF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTLKMFABBV
Forward yield8.19%3.06%
Annual dividend / share$0.01$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR9%40.6%
Portfolio after 10y$46.9K$102.3K
Annual income after 10y$4,206.70$24,771.77
Total dividends collected$21.6K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: TLKMF vs ABBV ($10,000, DRIP)

YearTLKMF PortfolioTLKMF Income/yrABBV PortfolioABBV Income/yrGap
1$11,592$892.44$11,550$430.00+$42.00TLKMF
2← crossover$13,458$1,053.89$13,472$627.96$14.00ABBV
3$15,646$1,246.34$15,906$926.08$260.00ABBV
4$18,218$1,476.10$19,071$1,382.55$853.00ABBV
5$21,244$1,750.81$23,302$2,095.81$2.1KABBV
6$24,810$2,079.78$29,150$3,237.93$4.3KABBV
7$29,021$2,474.39$37,536$5,121.41$8.5KABBV
8$34,001$2,948.47$50,079$8,338.38$16.1KABBV
9$39,901$3,518.98$69,753$14,065.80$29.9KABBV
10$46,900$4,206.70$102,337$24,771.77$55.4KABBV

TLKMF vs ABBV: Complete Analysis 2026

TLKMFStock

Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk provides telecommunications, informatics, and network services worldwide. The company's Mobile segment offers mobile voice, SMS, and mobile broadband services; and digital services, including financial services, video on demand, music, gaming, IoT, big data analytics, and digital advertising services. Its Consumer segment provides fixed voice and broadband services; and IPTV and related consumer digital services. The company's Enterprise segment offers ICT and digital platform that covers enterprise-grade connectivity services, including satellite, IT services, data center and cloud, and business process outsourcing services, as well as CPE trading and managed, cyber security, financial, big data, digital advertising, e-health, managed ATM, and professional services. Its Wholesale and International Business segment provides wholesale voice, managed, A2P SMS, IP transit and connectivity, data center and cloud, security, and value added and digital services; mobile network operator, mobile virtual network operator, and call center services; and tower and infrastructure services to other licensed operator companies and institutions. The company's Others segment offers digital services, such as digital platform, digital content, and e-commerce; and property management services. The company also provides building management and maintenance services, payment, business management consulting and capital venture, health insurance administration, tourism, directory information, telecommunication construction, and multimedia portal services; acts as a civil consultant and developer; and leases offices. As of December 31, 2020, it had approximately 9.1 million fixed wireline subscribers, including 8.0 million fixed broadband subscribers; and 169.5 million cellular subscribers, including 115.9 million mobile broadband subscribers. The company was founded in 1884 and is headquartered in Bandung, Indonesia.

Full TLKMF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TLKMF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TLKMF vs SCHDTLKMF vs JEPITLKMF vs OTLKMF vs KOTLKMF vs MAINTLKMF vs JNJTLKMF vs MRKTLKMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.